LeMaitre Vascular’s (LMAT) Outperform Rating Reiterated at Barrington Research

Barrington Research reaffirmed their outperform rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $92.00 target price on the medical instruments supplier’s stock.

LMAT has been the subject of a number of other research reports. JMP Securities raised their price target on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the stock a market outperform rating in a report on Tuesday, August 20th. Roth Capital raised LeMaitre Vascular to a strong-buy rating in a research report on Friday, May 31st. StockNews.com lowered LeMaitre Vascular from a buy rating to a hold rating in a report on Tuesday, August 27th. Roth Mkm reaffirmed a buy rating and set a $100.00 target price on shares of LeMaitre Vascular in a report on Friday, May 31st. Finally, Lake Street Capital began coverage on shares of LeMaitre Vascular in a report on Friday, August 2nd. They issued a buy rating and a $105.00 price target on the stock. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, LeMaitre Vascular presently has an average rating of Moderate Buy and a consensus price target of $94.40.

LeMaitre Vascular Stock Up 1.6 %

Shares of NASDAQ:LMAT opened at $91.41 on Friday. The firm has a 50 day moving average of $86.94 and a 200 day moving average of $78.30. The company has a market capitalization of $2.05 billion, a price-to-earnings ratio of 60.54, a price-to-earnings-growth ratio of 2.28 and a beta of 0.88. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $92.90.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Thursday, August 1st. The medical instruments supplier reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The company had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a net margin of 18.33% and a return on equity of 12.41%. LeMaitre Vascular’s revenue for the quarter was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.37 earnings per share. On average, sell-side analysts expect that LeMaitre Vascular will post 1.85 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, August 29th. Shareholders of record on Thursday, August 15th were issued a $0.16 dividend. The ex-dividend date was Thursday, August 15th. This represents a $0.64 annualized dividend and a yield of 0.70%. LeMaitre Vascular’s payout ratio is 42.38%.

Insider Activity

In related news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the transaction, the chief executive officer now owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total value of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares in the company, valued at $168,944,956.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 12,976 shares of the stock in a transaction dated Friday, July 12th. The shares were sold at an average price of $86.07, for a total value of $1,116,844.32. Following the completion of the sale, the chief executive officer now directly owns 1,985,358 shares in the company, valued at approximately $170,879,763.06. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 43,251 shares of company stock valued at $3,714,994. 10.79% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LMAT. CANADA LIFE ASSURANCE Co boosted its holdings in shares of LeMaitre Vascular by 44.7% in the first quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock valued at $1,472,000 after acquiring an additional 6,875 shares during the period. Quantbot Technologies LP grew its position in LeMaitre Vascular by 1,001.4% during the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after purchasing an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. increased its stake in LeMaitre Vascular by 1.5% in the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock valued at $51,794,000 after purchasing an additional 13,681 shares during the period. Congress Asset Management Co. MA raised its holdings in shares of LeMaitre Vascular by 12.0% in the first quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after buying an additional 71,411 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock worth $87,914,000 after buying an additional 38,303 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.